Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

how that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, June 27, 2007 and September 26, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303-516-8500.

Contact:

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Lilian Stern

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Dana Conti

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com

Tapestry Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thou
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... FL (May 4, 2009): Uveitis, or inflammation within ... for years of visual loss roughly comparable to ... pioneering international Phase 3 program in uveitis, the ... ability of LX211 (LUVENIQ, voclosporin oral capsule) to ...
... Changes Will Result in a 35% Sales Force Reduction ... DIEGO, May 4 Amylin Pharmaceuticals, Inc. (Nasdaq: ... sales within the diabetes market. Amylin,s existing primary care ... organization that brings a specialty approach to endocrinologists and ...
... Diagnostics, LLC. (MSD) confirmed today that its investigational influenza ... of infection with the 2009 A(H1N1) swine flu. ... being developed under a contract with the Centers for ... referred to in the CDC,s Morbidity and Mortality Weekly ...
Cached Biology Technology:First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 2Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 3Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 4Meso Scale Diagnostics' Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Texas AgriLife Research program at Vernon could become a ... Malinowski, Texas AgriLife Research plant physiologist and forage agronomist ... early start about six years ago as a hobby ... Pinchak, AgriLife Research animal nutritionist, and Steve Brown, Texas ...
... "Paper of the Week" by Wai Mun Huang and ... the University of Minnesota reveals new insights into the molecular ... the pathogen responsible for crown gall disease, a tumor-forming infection ... The bacterium is parasitic: It infects its plant ...
... at the Northeast Fisheries Science Center,s Narragansett Laboratory, ... primary productivity and dissolved oxygen would lead. Now ... heads a long-term Ship of Opportunity Program (SOOP) ... platforms during their routine operations. Using an instrument, ...
Cached Biology News:Researchers take hibiscus efforts to commercialization 2Researchers take hibiscus efforts to commercialization 3NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 2NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 3
... monoclonal antibody which can immunocapture up to ... mitochondria. Also included are 2 mg of ... Complex V immunocapture kit allows isolation of ... small amounts of tissue. This facilitates subsequent ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
... Rabbit polyclonal to MKK6 (phospho S207) ... applications). Antigen: ... around the phosphorylation site of Serine ... Entrez Gene ID: 5608 ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: